Patients taking MTX were randomized ( 1:1:1 ) to receive fostamatinib 100 mg twice daily for 52 weeks ( group A ) , fostamatinib 100 mg twice daily for 4 weeks and then 150 mg once daily ( group B ) , or placebo for 24 weeks and then fostamatinib 100 mg twice daily ( group C ) .